To be presented: Tuesday, April 20, 2:00 5:00 pm; Exhibit Hall A-C, Poster Section 2; Board 5
Arsenic trioxide inhibits Ewing sarcoma growth by blocking Hedgehog/GLI pathway (Abstract # 3409)
EMBARGO: Tuesday, April 20, 2010; 9:00 am ET
Author's summary: "The protein GLI1 is important for the growth of many cancers such as pancreatic and brain tumors. We have previously published that the protein GLI1 is important for the growth of Ewing Sarcoma. We show data that an already FDA approved drug Arsenic Trioxide which is used to treat a specific type of leukemia can inhibit the protein GLI1. Arsenic Trioxide can inhibit the growth of a specific type of pediatric brain cancer called Medulloblastoma as well as Ewing sarcoma in mice. Therefore Arsenic Trioxide can be investigated in clinical trials to treat Ewing Sarcoma as well as other types of cancers that depend on hyperactivity of the protein GLI1." Elspeth M. Beauchamp
Authors: Elspeth M. Beauchamp, Olga Rodriguez, Christopher Albanese, Jeffrey A. Toretsky, and Aykut ren, from. Georgetown Lombardi Comp. Cancer Ctr., Washington, DCBeauchamp
To be presented: Tuesday, April 20, 9:00 am - 12:00 pm ET, Exhibit Hall A-C, Poster Section 18, Board 10
EWS-FLI1 as a molecular target: Small molecule inhibitors for a disordered protein (Abstract #2681)
EMBARGO: Monday, April 19, 2010; 2:00 pm ET
Author's summary: "Ewing's sarcoma family of tumors are characterized by the EWS-FLI1 oncogenic fusion protein. Previous studies show that RNA Helicase A (RHA) binds with EWS-FLI1 to enhances the oncogensis of EWS-FLI1 and the interaction between these two proteins can be disrupted by small molecule inhibitors. To test analogues of the lead small molecule, a biophysical assay is necessary to determine binding. AlphaScreen technology allows for a peptide displacement assay to study binding in a 96 well plate format
'/>"/>
| Contact: Karen Mallet km463@georgetown.edu 215-514-9751 Georgetown University Medical Center Source:Eurekalert |